表紙
市場調査レポート

PharmaPoint:パーキンソン病 - ブラジルにおける医薬品の予測と市場分析

PharmaPoint: Parkinson's Disease - Brazil Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 301427
出版日 ページ情報 英文 167 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
PharmaPoint:パーキンソン病 - ブラジルにおける医薬品の予測と市場分析 PharmaPoint: Parkinson's Disease - Brazil Drug Forecast and Market Analysis to 2022
出版日: 2014年03月31日 ページ情報: 英文 167 Pages
概要

パーキンソン病は、動作緩慢、筋硬直、振戦、姿勢の不安定で特徴づけられる進行性の症状です。2番目に高頻度の神経変性障害で、どの年齢層にも影響を及ぼす可能性があり、有病率は加齢とともに上昇し、高齢者によく見られます。動作緩慢には、ドーパミン療法がかなり効果的ですが、いくつかのアンメットニーズが残されています。

当レポートでは、ブラジルにおけるパーキンソン病の治療薬市場について調査分析し、疾病の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
    • QOL
  • 症状

第4章 疾病の管理

  • 概要
  • 治療の概要
  • パーキンソン病の評価規模
  • パーキンソン病の診断と治療:国別
    • ブラジル

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - レボドパ混合製剤
  • 製品プロファイル - COMT阻害薬
  • ドーパミン作動薬
  • 製品プロファイル - MAO-B阻害薬
  • 製品プロファイル - アデノシンA2A受容体拮抗薬
  • 製品プロファイル - その他の治療法

第6章 機会とアンメットニーズ

  • 概要
  • 運動合併症の治療
  • 非運動合併症の治療
  • 神経保護/予防維持薬
  • 製剤の改善
  • 信頼性の高いバイオマーカー
  • 臨床試験設計の改善

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
    • Safinamide
    • Mavoglurant/AFQ056
    • CD/LD-GR
    • その他の後期パイプライン製品

第8章 現在/将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Merck
    • Roche
    • AbbVie
    • UCB
    • GlaxoSmithKline
    • Novartis
    • Orion
    • Newron
    • Civitas
    • Impax
    • Lundbeck

第9章 市場の見通し

  • ブラジル

第10章 付録

図表

目次
Product Code: GDHC238CFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

The decline in sales is attributed to a private-public partnership (PPP) between Brazil and Boehringer Ingelheim, which will drive down the price of generic pramipexole as the technology to produce the drug is transferred to Brazil's Oswaldo Cruz Foundation (Fiocruz)/Institute of Drug Technology (Farmanguinhos), which will solely be responsible for the country's production of the drug by 2017.

Scope

  • Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Brazil from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Brazil Parkinson's Disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's Disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Brazil

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments
  • 4.4. Diagnosis and Treatment of Parkinson's Disease by Country
    • 4.4.1. Brazil

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Levodopa Combination Therapy
    • 5.3.1. Madopar (levodopa/benserazide)
    • 5.3.2. Sinemet (carbidopa/levodopa)
  • 5.4. Product Profiles - COMT Inhibitors
    • 5.4.1. Stalevo/Comtan (entacapone)
  • 5.5. Dopamine Agonists
    • 5.5.1. Neupro (rotigotine transdermal patch)
  • 5.6. Product Profiles - MAO-B Inhibitors
    • 5.6.1. Azilect (rasagiline)
  • 5.7. Product Profiles - Other Therapies

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Treatment of Motor Complications - Dyskinesias and OFF Episodes
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Treatment of Non-Motor Symptoms and Dementia
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Neuroprotective/Disease-Modifying Agents
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Identification of Reliable Biomarkers
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improved Clinical Trial Design
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Safinamide
    • 7.2.2. Mavoglurant/AFQ056
    • 7.2.3. CD/LD-GR
    • 7.2.4. Other Late-Stage Pipeline Products

8. Current and Future Players

  • 8.1. Overview
  • 8.2. Trends in Corporate Strategy
  • 8.3. Company Profiles
    • 8.3.1. Merck
    • 8.3.2. Roche
    • 8.3.3. AbbVie
    • 8.3.4. UCB
    • 8.3.5. GlaxoSmithKline
    • 8.3.6. Novartis
    • 8.3.7. Orion
    • 8.3.8. Newron
    • 8.3.9. Civitas
    • 8.3.10. Impax
    • 8.3.11. Lundbeck

9. Market Outlook

  • 9.1. Brazil
    • 9.1.1. Forecast
    • 9.1.2. Key Events
    • 9.1.3. Drivers and Barriers - Global Issues
    • 9.1.4. Drivers and Barriers - Brazil

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Parkinson's disease Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Compliance Assumptions
    • 10.4.7. Individual Drug Assumptions
    • 10.4.8. Generic Erosion
    • 10.4.9. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Parkinson's Disease, Country Profile - Brazil
  • Table 9: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 10: Leading Treatments for Parkinson's Disease, 2014
  • Table 11: Product Profile - Madopar
  • Table 12: Madopar SWOT Analysis, 2014
  • Table 13: Product Profile - Sinemet
  • Table 14: Sinemet SWOT Analysis, 2014
  • Table 15: Product Profile - Stalevo
  • Table 16: Product Profile - Comtan
  • Table 17: Stalevo/Comtan SWOT Analysis, 2014
  • Table 18: Product Profile - Neupro
  • Table 19: Neupro SWOT Analysis, 2014
  • Table 20: Product Profile - Azilect
  • Table 21: Azilect SWOT Analysis, 2014
  • Table 22: Summary of Alternative Parkinson's Disease Therapies
  • Table 23: Unmet Need and Opportunity in Parkinson's Disease
  • Table 24: Dyskinesia Pipeline, 2014
  • Table 25: Dementia Pipeline, 2014
  • Table 26: Parkinson's Disease-Modifying Therapeutics Pipeline, 2014
  • Table 27: Product Profile - Safinamide
  • Table 28: Summary of Relevant Clinical Trials for Safinamide
  • Table 29: Safinamide SWOT Analysis, 2014
  • Table 30: Product Profile - Mavoglurant
  • Table 31: Mavoglurant SWOT Analysis, 2014
  • Table 32: Product Profile - CD/LD-GR
  • Table 33: Summary of Relevant Clinical Trials for CD/LD-GR
  • Table 34: CD/LD-GR SWOT Analysis, 2014
  • Table 35: Late-Stage Pipeline, 2013
  • Table 36: Key Companies in the Parkinson's Market, 2014
  • Table 37: Merck's Parkinson's Disease Portfolio Assessment, 2014
  • Table 38: Merck's PD SWOT Analysis, 2014
  • Table 39: Roche's Parkinson's Disease Portfolio Assessment, 2014
  • Table 40: Roche's PD SWOT Analysis, 2014
  • Table 41: AbbVie's Parkinson's Disease Portfolio Assessment, 2014
  • Table 42: AbbVie's PD SWOT Analysis, 2014
  • Table 43: UCB's Parkinson's Disease Portfolio Assessment, 2014
  • Table 44: UCB's PD SWOT Analysis, 2014
  • Table 45: GSK's Parkinson's Disease Portfolio Assessment, 2014
  • Table 46: GSK's PD SWOT Analysis, 2014
  • Table 47: Novartis' Parkinson's Disease Portfolio Assessment, 2014
  • Table 48: Novartis' PD SWOT Analysis, 2014
  • Table 49: Orion's Parkinson's Disease Portfolio Assessment, 2014
  • Table 50: Orion's PD SWOT Analysis, 2014
  • Table 51: Newron's Parkinson's Disease Portfolio Assessment, 2014
  • Table 52: Newron's PD SWOT Analysis, 2014
  • Table 53: Civitas' Parkinson's Disease Portfolio Assessment, 2014
  • Table 54: Civitas' PD SWOT Analysis, 2014
  • Table 55: Impax's Parkinson's Disease Portfolio Assessment, 2014
  • Table 56: Impax's PD SWOT Analysis, 2014
  • Table 57: Lundbeck's Disease/Therapy Portfolio Assessment, 2014
  • Table 58: Lundbeck's SWOT Analysis, 2014
  • Table 59: Sales Forecasts ($m) for Parkinson's Disease in Brazil, 2012-2022
  • Table 60: Key Events Impacting Sales for Parkinson's Disease in Brazil, 2012-2022
  • Table 61: Parkinson's Disease Market - Drivers and Barriers, 2012-2022
  • Table 62: Parkinson's Disease Market in Brazil - Drivers and Barriers, 2012-2022
  • Table 63: Key Launch Dates
  • Table 64: Key Patent Expiries

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
  • Figure 3: Pharmacokinetics of Levodopa
  • Figure 4: Company Portfolio Gap Analysis in Parkinson's Motor Symptoms, 2012-2022
  • Figure 5: Sales for Parkinson's Disease in Brazil by Drug Class, 2012-2022
Back to Top